Skip to main content
Top
Published in: Diabetologia 5/2005

01-05-2005 | Article

Adiponectin and beta cell dysfunction in gestational diabetes: pathophysiological implications

Authors: R. Retnakaran, A. J. G. Hanley, N. Raif, C. R. Hirning, P. W. Connelly, M. Sermer, S. E. Kahn, B. Zinman

Published in: Diabetologia | Issue 5/2005

Login to get access

Abstract

Aims/hypothesis

Gestational diabetes mellitus (GDM) identifies a population of young women at high risk of developing type 2 diabetes and thus provides an excellent model for studying early events in the natural history of this disease. Adiponectin, a novel adipocyte-derived protein with insulin-sensitising properties, has been proposed as a factor linking insulin resistance and beta cell dysfunction in the pathogenesis of type 2 diabetes. We conducted the current investigation to determine whether adiponectin is associated with beta cell dysfunction in GDM.

Methods

We studied 180 women undergoing OGTT in late pregnancy. Based on the OGTT results, participants were stratified into three groups: (1) NGT (n=93); (2) IGT (n=39); and (3) GDM (n=48). First-phase insulin secretion was determined using a validated index previously proposed by Stumvoll. Insulin sensitivity was assessed using the validated OGTT insulin sensitivity index of Matsuda and DeFronzo (ISOGTT).

Results

To evaluate beta cell function in relation to ambient insulin sensitivity, an insulin secretion-sensitivity index (ISSI) was derived from the product of the Stumvoll index and the ISOGTT, based on the existence of the predicted hyperbolic relationship between these two measures. Mean ISSI was highest in the NGT group (6,731), followed by that in the IGT group (4,976) and then that in the GDM group (3,300) (overall p<0.0001), compatible with the notion of declining beta cell function across these glucose tolerance groups. Importantly, adiponectin was significantly correlated with ISSI (r=0.34, p<0.0001), with a stepwise increase in mean ISSI observed per tertile of adiponectin concentration (trend p<0.0001). In multivariate linear regression analysis, ISSI was positively correlated with adiponectin and negatively correlated with GDM, IGT and C-reactive protein (r 2=0.54).

Conclusions/interpretation

Adiponectin concentration is an independent correlate of beta cell function in late pregnancy. As such, adiponectin may play a key role in mediating insulin resistance and beta cell dysfunction in the pathogenesis of diabetes.
Literature
1.
go back to reference Kahn SE (2003) The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of type 2 diabetes. Diabetologia 46:3–19CrossRefPubMed Kahn SE (2003) The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of type 2 diabetes. Diabetologia 46:3–19CrossRefPubMed
2.
go back to reference Bergman RN, Phillips LS, Cobelli C (1981) Physiologic evaluation of factors controlling glucose tolerance in man: measurement of insulin sensitivity and β-cell glucose sensitivity from the response to intravenous glucose. J Clin Invest 68:1456–1467PubMed Bergman RN, Phillips LS, Cobelli C (1981) Physiologic evaluation of factors controlling glucose tolerance in man: measurement of insulin sensitivity and β-cell glucose sensitivity from the response to intravenous glucose. J Clin Invest 68:1456–1467PubMed
3.
go back to reference Kahn SE, Prigeon RL, McCulloch DK et al (1993) Quantification of the relationship between insulin sensitivity and β-cell function in human subjects: evidence for a hyperbolic function. Diabetes 42:1663–1672PubMed Kahn SE, Prigeon RL, McCulloch DK et al (1993) Quantification of the relationship between insulin sensitivity and β-cell function in human subjects: evidence for a hyperbolic function. Diabetes 42:1663–1672PubMed
4.
go back to reference Bergman RN, Finegood DT, Kahn SE (2002) The evolution of β-cell dysfunction and insulin resistance in type 2 diabetes. Eur J Clin Invest 32[Suppl 3]:35–45 Bergman RN, Finegood DT, Kahn SE (2002) The evolution of β-cell dysfunction and insulin resistance in type 2 diabetes. Eur J Clin Invest 32[Suppl 3]:35–45
5.
go back to reference Weyer C, Bogardus C, Mott DM, Pratley RE (1999) The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. J Clin Invest 104:787–794PubMed Weyer C, Bogardus C, Mott DM, Pratley RE (1999) The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. J Clin Invest 104:787–794PubMed
6.
go back to reference Bergman RN, Ader M, Huecking K, Van Citters G (2002) Accurate assessment of β-cell function: the hyperbolic correction. Diabetes 51[Suppl 1]:S212–S220 Bergman RN, Ader M, Huecking K, Van Citters G (2002) Accurate assessment of β-cell function: the hyperbolic correction. Diabetes 51[Suppl 1]:S212–S220
7.
go back to reference Greenberg AS, McDaniel ML (2002) Identifying the links between obesity, insulin resistance and β-cell function: potential role of adipocyte-derived cytokines in the pathogenesis of type 2 diabetes. Eur J Clin Invest 32[Suppl 3]24–34 Greenberg AS, McDaniel ML (2002) Identifying the links between obesity, insulin resistance and β-cell function: potential role of adipocyte-derived cytokines in the pathogenesis of type 2 diabetes. Eur J Clin Invest 32[Suppl 3]24–34
8.
go back to reference Ukkola O, Santaniemi M (2002) Adiponectin: a link between excess adiposity and associated comorbidities? J Mol Med 80:696–702 Ukkola O, Santaniemi M (2002) Adiponectin: a link between excess adiposity and associated comorbidities? J Mol Med 80:696–702
9.
go back to reference Berg AH, Combs TP, Scherer PE (2002) ACRP30/adiponectin: an adipokine regulating glucose and lipid metabolism. Trends Endocrinol Metab 13:84–89CrossRefPubMed Berg AH, Combs TP, Scherer PE (2002) ACRP30/adiponectin: an adipokine regulating glucose and lipid metabolism. Trends Endocrinol Metab 13:84–89CrossRefPubMed
10.
go back to reference Weyer C, Funahashi T, Tanaka S et al (2001) Hypoadiponectinemia in obesity and type 2 DM: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 86:1930–1935CrossRefPubMed Weyer C, Funahashi T, Tanaka S et al (2001) Hypoadiponectinemia in obesity and type 2 DM: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 86:1930–1935CrossRefPubMed
11.
go back to reference Arita Y, Kihara S, Ouchi N et al (1999) Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 257:79–93CrossRefPubMed Arita Y, Kihara S, Ouchi N et al (1999) Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 257:79–93CrossRefPubMed
12.
go back to reference Cnop M, Havel PJ, Utzschneider KM et al (2003) Relationship of adiponectin to body fat distribution, insulin sensitivity and plasma lipoproteins: evidence for independent roles of age and sex. Diabetologia 46:459–469PubMed Cnop M, Havel PJ, Utzschneider KM et al (2003) Relationship of adiponectin to body fat distribution, insulin sensitivity and plasma lipoproteins: evidence for independent roles of age and sex. Diabetologia 46:459–469PubMed
13.
go back to reference Hotta K, Funahashi T, Arita Y et al (2000) Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol 20:1595–1599PubMed Hotta K, Funahashi T, Arita Y et al (2000) Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol 20:1595–1599PubMed
14.
go back to reference Stefan N, Vozarova B, Funahashi T et al (2002) Plasma adiponectin concentration is associated with skeletal muscle insulin receptor tyrosine phosphorylation, and low plasma concentration precedes a decrease in whole-body insulin sensitivity in humans. Diabetes 50:1884–1888 Stefan N, Vozarova B, Funahashi T et al (2002) Plasma adiponectin concentration is associated with skeletal muscle insulin receptor tyrosine phosphorylation, and low plasma concentration precedes a decrease in whole-body insulin sensitivity in humans. Diabetes 50:1884–1888
15.
go back to reference Lindsay RS, Funahashi T, Hanson RL et al (2002) Adiponectin and development of type 2 diabetes in the Pima Indian population. Lancet 360:57–58CrossRefPubMed Lindsay RS, Funahashi T, Hanson RL et al (2002) Adiponectin and development of type 2 diabetes in the Pima Indian population. Lancet 360:57–58CrossRefPubMed
16.
go back to reference Spranger J, Kroke A, Mohlig M (2003) Adiponectin and protection against type 2 diabetes mellitus. Lancet 361:226–228CrossRefPubMed Spranger J, Kroke A, Mohlig M (2003) Adiponectin and protection against type 2 diabetes mellitus. Lancet 361:226–228CrossRefPubMed
17.
go back to reference Snehalatha C, Mukesh B, Simon M, Vishwanathan V, Haffner SM, Ramachandran A (2003) Plasma adiponectin is an independent predictor of type 2 diabetes in Asian Indians. Diabetes Care 26:3226–3229 Snehalatha C, Mukesh B, Simon M, Vishwanathan V, Haffner SM, Ramachandran A (2003) Plasma adiponectin is an independent predictor of type 2 diabetes in Asian Indians. Diabetes Care 26:3226–3229
18.
go back to reference Daimon M, Oizumi T, Saitoh T et al (2003) Decreased serum levels of adiponectin are a risk factor for the progression to type 2 diabetes in the Japanese Population: the Funagata study. Diabetes Care 26:2015–2020 Daimon M, Oizumi T, Saitoh T et al (2003) Decreased serum levels of adiponectin are a risk factor for the progression to type 2 diabetes in the Japanese Population: the Funagata study. Diabetes Care 26:2015–2020
19.
go back to reference Kjos SL, Buchanan TA (1999) Gestational diabetes mellitus. N Engl J Med 341:1749–1756 Kjos SL, Buchanan TA (1999) Gestational diabetes mellitus. N Engl J Med 341:1749–1756
20.
go back to reference Buchanan TA (2001) Pancreatic β-cell defects in gestational diabetes: implications for the pathogenesis and prevention of type 2 diabetes. J Clin Endocrinol Metab 86:989–993 Buchanan TA (2001) Pancreatic β-cell defects in gestational diabetes: implications for the pathogenesis and prevention of type 2 diabetes. J Clin Endocrinol Metab 86:989–993
21.
go back to reference Ward WK, Johnston CL, Beard JC, Benedetti TJ, Halter JB, Porte D Jr (1985) Insulin resistance and impaired insulin secretion in subjects with histories of gestational diabetes mellitus. Diabetes 34:861–869 Ward WK, Johnston CL, Beard JC, Benedetti TJ, Halter JB, Porte D Jr (1985) Insulin resistance and impaired insulin secretion in subjects with histories of gestational diabetes mellitus. Diabetes 34:861–869
22.
go back to reference Retnakaran R, Hanley AJG, Raif N, Connelly PW, Sermer M, Zinman B (2004) Reduced adiponectin concentration in women with gestational diabetes: a potential factor in progression to type 2 diabetes. Diabetes Care 27:799–800 Retnakaran R, Hanley AJG, Raif N, Connelly PW, Sermer M, Zinman B (2004) Reduced adiponectin concentration in women with gestational diabetes: a potential factor in progression to type 2 diabetes. Diabetes Care 27:799–800
23.
go back to reference Retnakaran R, Hanley AJG, Raif N, Connelly PW, Sermer M, Zinman B (2003) C-reactive protein and gestational diabetes: the central role of maternal obesity. J Clin Endocrinol Metab 88:3507–3512 Retnakaran R, Hanley AJG, Raif N, Connelly PW, Sermer M, Zinman B (2003) C-reactive protein and gestational diabetes: the central role of maternal obesity. J Clin Endocrinol Metab 88:3507–3512
24.
go back to reference National Diabetes Data Group (1979) Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. Diabetes 28:1039–1057 National Diabetes Data Group (1979) Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. Diabetes 28:1039–1057
25.
go back to reference Matsuda M, DeFronzo R (1999) Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care 22:1462–1470 Matsuda M, DeFronzo R (1999) Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care 22:1462–1470
26.
go back to reference Katz A, Nambi SS, Mather K et al (2000) Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. J Clin Endocrinol Metab 85:2402–2410CrossRefPubMed Katz A, Nambi SS, Mather K et al (2000) Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. J Clin Endocrinol Metab 85:2402–2410CrossRefPubMed
27.
go back to reference Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC (1985) Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetes 28:412–419 Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC (1985) Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetes 28:412–419
28.
go back to reference Kirwan JP, Huston-Presley L, Kalhan SC, Catalano PM (2001) Clinically useful estimates of insulin sensitivity during pregnancy: validation studies in women with normal glucose tolerance and gestational diabetes mellitus. Diabetes Care 24:1602–1607 Kirwan JP, Huston-Presley L, Kalhan SC, Catalano PM (2001) Clinically useful estimates of insulin sensitivity during pregnancy: validation studies in women with normal glucose tolerance and gestational diabetes mellitus. Diabetes Care 24:1602–1607
29.
go back to reference Stumvoll M, Van Haeften TV, Fritsche A, Gerich J (2001) Oral glucose tolerance test indexes for insulin sensitivity and secretion based on various availabilities of sampling times. Diabetes Care 24:796–797PubMed Stumvoll M, Van Haeften TV, Fritsche A, Gerich J (2001) Oral glucose tolerance test indexes for insulin sensitivity and secretion based on various availabilities of sampling times. Diabetes Care 24:796–797PubMed
30.
go back to reference Stumvoll M, Mitrakou A, Pimenta W et al (2000) Use of the oral glucose tolerance test to assess insulin release and insulin sensitivity. Diabetes Care 23:295–301PubMed Stumvoll M, Mitrakou A, Pimenta W et al (2000) Use of the oral glucose tolerance test to assess insulin release and insulin sensitivity. Diabetes Care 23:295–301PubMed
31.
go back to reference Phillips DIW, Clark PM, Hales CN, Osmond B (1994) Understanding oral glucose tolerance: comparisons of glucose or insulin measurements during the oral glucose tolerance test with specific measurements of insulin resistance and insulin secretion. Diabet Med 11:286–292 Phillips DIW, Clark PM, Hales CN, Osmond B (1994) Understanding oral glucose tolerance: comparisons of glucose or insulin measurements during the oral glucose tolerance test with specific measurements of insulin resistance and insulin secretion. Diabet Med 11:286–292
32.
go back to reference Williams K, Hanley AJG, Haffner SM, Stern MP (2003) Predicting diabetes with insulin secretion measures in the San Antonio Heart Study. Diabetes Metab 29:5S20 Williams K, Hanley AJG, Haffner SM, Stern MP (2003) Predicting diabetes with insulin secretion measures in the San Antonio Heart Study. Diabetes Metab 29:5S20
33.
go back to reference Hanson RL, Pratley RE, Bogardus C et al (2000) Evaluation of simple indices of insulin sensitivity and insulin secretion for use in epidemiologic studies. Am J Epidemiol 151:190–198 Hanson RL, Pratley RE, Bogardus C et al (2000) Evaluation of simple indices of insulin sensitivity and insulin secretion for use in epidemiologic studies. Am J Epidemiol 151:190–198
34.
go back to reference Jensen C, Cnop M, Hull RL, Fujimoto WY, Kahn SE and the American Diabetes Association GENNID Study Group (2002) β-cell function is a major contributor to oral glucose tolerance in high-risk relatives of four ethnic groups in the US. Diabetes 51:2170–2178PubMed Jensen C, Cnop M, Hull RL, Fujimoto WY, Kahn SE and the American Diabetes Association GENNID Study Group (2002) β-cell function is a major contributor to oral glucose tolerance in high-risk relatives of four ethnic groups in the US. Diabetes 51:2170–2178PubMed
35.
go back to reference Guldstrand M, Ahren B, Adamson U (2003) Improved β-cell function after standardized weight reduction in severely obese subjects. Am J Physiol Endocrinol Metab 284:E557–E565 Guldstrand M, Ahren B, Adamson U (2003) Improved β-cell function after standardized weight reduction in severely obese subjects. Am J Physiol Endocrinol Metab 284:E557–E565
36.
go back to reference Winzer C, Wagner O, Festa A et al (2004) Plasma adiponectin, insulin sensitivity, and subclinical inflammation in women with prior gestational diabetes mellitus. Diabetes Care 27:1721–1727 Winzer C, Wagner O, Festa A et al (2004) Plasma adiponectin, insulin sensitivity, and subclinical inflammation in women with prior gestational diabetes mellitus. Diabetes Care 27:1721–1727
37.
go back to reference Bacha F, Saad R, Gungor N, Arslanian SA (2004) Adiponectin in youth: relationship to visceral adiposity, insulin sensitivity, and β-cell function. Diabetes Care 27:547–552 Bacha F, Saad R, Gungor N, Arslanian SA (2004) Adiponectin in youth: relationship to visceral adiposity, insulin sensitivity, and β-cell function. Diabetes Care 27:547–552
38.
go back to reference Yamauchi T, Kamon J, Waki H et al (2003) Globular adiponectin protected ob/ob mice from diabetes and ApoE-deficient mice from atherosclerosis. J Biol Chem 278:2461–2468PubMed Yamauchi T, Kamon J, Waki H et al (2003) Globular adiponectin protected ob/ob mice from diabetes and ApoE-deficient mice from atherosclerosis. J Biol Chem 278:2461–2468PubMed
39.
go back to reference Kharroubi I, Rasschaert J, Eizirik DL, Cnop M (2003) Expression of adiponectin receptors in pancreatic β-cells. Biochem Biophys Res Commun 312:1118–1122 Kharroubi I, Rasschaert J, Eizirik DL, Cnop M (2003) Expression of adiponectin receptors in pancreatic β-cells. Biochem Biophys Res Commun 312:1118–1122
40.
go back to reference Winzell MS, Nogueiras R, Dieguez C, Ahren B (2004) Dual action of adiponectin on insulin secretion in insulin-resistant mice. Biochem Biophys Res Commun 321:154–160 Winzell MS, Nogueiras R, Dieguez C, Ahren B (2004) Dual action of adiponectin on insulin secretion in insulin-resistant mice. Biochem Biophys Res Commun 321:154–160
41.
go back to reference Okamoto M, Ohara-Imaizumi M, Eto K et al (2004) Adiponectin stimulates insulin secretion via stimulation of insulin secretory granule. Diabetes 53[Suppl 2]:A39 Okamoto M, Ohara-Imaizumi M, Eto K et al (2004) Adiponectin stimulates insulin secretion via stimulation of insulin secretory granule. Diabetes 53[Suppl 2]:A39
42.
go back to reference Kwon G, Xu G, Marshall CA, McDaniel ML (1999) Tumor necrosis factor alpha-induced pancreatic beta-cell insulin resistance is mediated by nitric oxide and prevented by 15-deoxy-Delta12,14-prostaglandin J2 and aminoguanidine: a role for peroxisome proliferator-activated receptor gamma activation and inos expression. J Biol Chem 274:18702–18708 Kwon G, Xu G, Marshall CA, McDaniel ML (1999) Tumor necrosis factor alpha-induced pancreatic beta-cell insulin resistance is mediated by nitric oxide and prevented by 15-deoxy-Delta12,14-prostaglandin J2 and aminoguanidine: a role for peroxisome proliferator-activated receptor gamma activation and inos expression. J Biol Chem 274:18702–18708
43.
go back to reference Thamer C, Machann J, Tschritter O et al (2002) Relationship between serum adiponectin concentration and intramyocellular lipid stores in humans. Horm Metab Res 34:646–649CrossRefPubMed Thamer C, Machann J, Tschritter O et al (2002) Relationship between serum adiponectin concentration and intramyocellular lipid stores in humans. Horm Metab Res 34:646–649CrossRefPubMed
44.
go back to reference Rakatzi I, Mueller H, Ritzeler O, Tennagels N, Eckel J (2004) Adiponectin counteracts cytokine- and fatty acid-induced apoptosis in the pancreatic beta-cell line INS-1. Diabetologia 47:249–258 Rakatzi I, Mueller H, Ritzeler O, Tennagels N, Eckel J (2004) Adiponectin counteracts cytokine- and fatty acid-induced apoptosis in the pancreatic beta-cell line INS-1. Diabetologia 47:249–258
45.
go back to reference Cavaghan MK, Ehrmann DA, Polonsky KS (2000) Interactions between insulin resistance and insulin secretion in the development of glucose intolerance. J Clin Invest 106:329–333 Cavaghan MK, Ehrmann DA, Polonsky KS (2000) Interactions between insulin resistance and insulin secretion in the development of glucose intolerance. J Clin Invest 106:329–333
Metadata
Title
Adiponectin and beta cell dysfunction in gestational diabetes: pathophysiological implications
Authors
R. Retnakaran
A. J. G. Hanley
N. Raif
C. R. Hirning
P. W. Connelly
M. Sermer
S. E. Kahn
B. Zinman
Publication date
01-05-2005
Publisher
Springer-Verlag
Published in
Diabetologia / Issue 5/2005
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-005-1710-x

Other articles of this Issue 5/2005

Diabetologia 5/2005 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.